State Street Reports 4.7% Rigel Stake While Drug Sales Rise And Quarterly Profit Falls
The passive holding covered 879,862 shares as of September 30; Rigel still expects positive full-year net income.
State Street reported a 4.7% stake in Rigel Pharmaceuticals, which develops and sells drugs for blood disorders and cancer, in an SEC passive ownership disclosure filed Tuesday. The holding comprised 879,862 common shares as of September 30, 2026, while Rigel's latest quarter paired rising product sales with falling net income.
A Holding Without A Control Push
State Street certified that its holding arose from ordinary business activity and that it did not acquire or hold the shares to change or influence Rigel's control. The September position is an ownership reading, rather than a report of purchases made Tuesday.
State Street reported shared voting power over 858,066 shares and shared power to dispose of 879,862 shares. Rigel's market value was $792 million in Tuesday trading as of 10:02 a.m. ET.
More Sales, Less Profit
Rigel's third-quarter net income fell to $13.2 million from $27.9 million a year earlier. Product sales reached $72.3 million, a 13% year-over-year increase that the company called a record.
Costs and expenses totaled $63.8 million, compared with $41 million a year earlier. Rigel attributed part of that increase to research and commercial spending.
Cash, cash equivalents and short-term investments stood at $99.3 million, down from $155 million at the end of 2025. Rigel continued to expect positive net income for the full year.
Three Medicines And An R289 Plan
Rigel markets three FDA-approved medicines in the United States. Tavalisse treats adults with chronic immune thrombocytopenia, in which the immune system destroys blood platelets. Rezlidhia treats adults whose acute myeloid leukemia has returned or resisted treatment and carries an IDH1 mutation; Gavreto treats certain lung and thyroid cancers with RET fusions.
In 2025, net product sales were $158.8 million for Tavalisse, $42.1 million for Gavreto and $31 million for Rezlidhia. Rigel targets U.S. hematologists and blood-cancer specialists, while partners sell Tavalisse in Europe, Japan, Canada and Israel.
R289 is in an ongoing early-stage study for lower-risk myelodysplastic syndromes. Rigel plans a registration program for the drug in 2027.
Sources
- SCHEDULE 13G — STATE STREET CORPORATION re: RIGEL PHARMACEUTICALS INC (RIGL) — SEC EDGAR
- Rigel Pharmaceuticals Inc (RIGL) (Q3 2026) Earnings Call Highlights: Record Product Sales of ... — Yahoo Finance
- Rigel to Present at the Jefferies Global Healthcare Conference in London — prnewswire.com